Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Coagulation cascade
- Hemophilia
- Factor VIII
- Diverse new treatment options
- Inhibitor formation
- Inhibitor formation against FVIII
- Restoring hemostasis in inhibitor patients
- Immune tolerance induction (ITI)
- Novel approaches to ITI for FVIII
- Treg-mediated suppression
- Ex vivo expansion of autologous Treg
- Infectious tolerance
- Reprogramming T cells into Tregs
- Ex vivo enrichment for FVIII-specific Treg
- Redirecting antigen-specificity to Treg
- Treg with chimeric antigen receptor (CAR) for FVIII
- Ex vivo expansion of CAR-Treg
- Treg with FVIII B antigen receptor
- Tolerance induction using antigen & rapamycin
- Shifting the balance of responses to Treg
- FVIII tolerance induction using rapamycin (1)
- FVIII tolerance induction using rapamycin (2)
- Adeno-associated virus gene therapy
- FIX tolerance induction: AAV gene therapy
- Optimized hepatic AAV gene therapy
- Inhibitor reversal
- Hepatic AAV gene transfer (1)
- Hepatic AAV gene transfer (2)
- Plant-based oral tolerance for hemophilia
- Treg induction by oral tolerance
- Oral tolerance mechanism
- Suppression of inhibitor formation
- Pros of new tolerance approaches
- Cons of new tolerance approaches
- Financial disclosure
- Acknowledgements (trainees)
- Acknowledgements (collaborators)
- Thank you
Topics Covered
- Replacement therapy for patients with hemophilia utilizes Factor VIII
- Replacement therapy is rejected by the immune system
- Exploring immune tolerance to Factor VIII
- Engineering regulatory T cells therapy
- Various small molecular and monoclonal antibody drugs
- Hepatic AAV gene therapy
- Plant-based oral tolerance
Talk Citation
Herzog, R.W. (2020, June 30). Immune tolerance induction to factor VIII [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/KJIN2167.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Herzog serves on the scientific advisory board of Ally Therapeutics. He has received royalties from Takeda Pharmaceuticals for oral tolerance technologies and grant funding from Luye R&D for gene therapy research.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Roland Herzog.
I'm the Director of the Gene and Cell Therapy Program at
the Hermann B. Wells Center for Pediatric Research at Indiana University.
I would like to talk to you about immune tolerance induction to coagulation factor VIII.
0:18
Our body is able to heal injuries that
happen to our blood vessels by forming a blood clot.
The formation of this blood clot that seals
an injured vessel requires a cascade of enzymatic reaction that happen in the blood,
and the proteins that carry out these reactions are referred to as coagulation factors.
It turns out that if one of these coagulation factors is defective,
the blood loses the ability to clot.
For example, factor IX is an enzyme that is
part of this cascade that is critical to carry out one of these reactions,
and it has a cofactor called factor VIII,
which is required for factor IX to function properly.
Deficiencies through genetic mutations in either of these two proteins
disrupt the coagulation cascade so that the blood is no longer able to properly clot.
1:17
As a result, patients with mutations in either factor VIII or IX,
are born with a bleeding disorder called hemophilia.
In the case of factor VIII deficiency,
which is the more common form of the two diseases,
the disease is called hemophilia A.
Because both genes are X-linked,
it is boys that are born with the disease,
whereas females are carriers.
The incidence of hemophilia worldwide is approximately one in 5,000 male births.
The severity of the disease correlates with the levels of coagulation.
In other words, a more serious mutation which
results in greater loss of the ability of the blood to clot,
will result in more severe disease,
and those patients who have less than one percent of
normal coagulation activity will bleed frequently.
In this case, the disease is characterized by frequent spontaneous bleeding episodes,
which often occur into joints and soft tissues.
An example is shown here with a child having a joint bleed,
and bleeding into closed spaces can actually be fatal.